Governance

The structure of the National Cancer Registry is as follows:

The National Cancer Registry Board comprises seven members and meets four times a year.

Current members of the Board are:

Title	Organisation
Dr Robert O'Connor [1]	National Clinical Trials Office
Prof Mark Lawler [2]	Queen's University Belfast
Ms Mary Bourke [3]	GlaxoSmithKline, Schering Plough, Novartis, Wyeth, AbbVie, Pfizer and Bristol Myers Squibb
Ms Ellen Farrell [4]	Fidelity International - FIL Investment Management Limited
Mr Niall Murphy [5]	Salesforce
Ms Cathy Enright [6]	Trinity St James’s Cancer Institute

Prof Deirdre Murray [7] is the Director of the National Cancer Registry, responsible for the implementation of the Board’s policies. The National Cancer Registry is divided into four functional areas [8], each of which reports to the Director.

Further information on governance is available in the Registry's Governance Framework [9], Code of Business Conduct [10], and Annual Financial Reports [11].